The authors validated their findings by conducting a meta-analysis using 16 studies that reported the association between CYP2C19 and NAFLD, which revealed that CYP2C19 was found to be significantly downregulated in 15 of the 16 studies [172]. Here, CYP2C19 is linked to metabolic dysfunction-associated steatotic liver disease.